These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20020537)

  • 1. A pharmacogenetic study of escitalopram in autism spectrum disorders.
    Owley T; Brune CW; Salt J; Walton L; Guter S; Ayuyao N; Gibbons RD; Leventhal BL; Cook EH
    Autism Res; 2010 Feb; 3(1):1-7. PubMed ID: 20020537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism.
    Najjar F; Owley T; Mosconi MW; Jacob S; Hur K; Guter SJ; Sweeney JA; Gibbons RD; Cook EH; Bishop JR
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):467-74. PubMed ID: 26262902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of citalopram in pervasive developmental disorders.
    Namerow L; Thomas P; Bostic JQ; Prince J; Monuteaux MC
    J Dev Behav Pediatr; 2003 Apr; 24(2):104-8. PubMed ID: 12692455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.
    King BH; Hollander E; Sikich L; McCracken JT; Scahill L; Bregman JD; Donnelly CL; Anagnostou E; Dukes K; Sullivan L; Hirtz D; Wagner A; Ritz L;
    Arch Gen Psychiatry; 2009 Jun; 66(6):583-90. PubMed ID: 19487623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.
    King BH; Dukes K; Donnelly CL; Sikich L; McCracken JT; Scahill L; Hollander E; Bregman JD; Anagnostou E; Robinson F; Sullivan L; Hirtz D
    JAMA Pediatr; 2013 Nov; 167(11):1045-52. PubMed ID: 24061784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia.
    Anderson GM; Gutknecht L; Cohen DJ; Brailly-Tabard S; Cohen JH; Ferrari P; Roubertoux PL; Tordjman S
    Mol Psychiatry; 2002; 7(8):831-6. PubMed ID: 12232775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation.
    Damsbo AG; Kraglund KL; Buttenschøn HN; Johnsen SP; Andersen G; Mortensen JK
    Cerebrovasc Dis; 2019; 47(1-2):72-79. PubMed ID: 30844812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label trial of escitalopram in pervasive developmental disorders.
    Owley T; Walton L; Salt J; Guter SJ; Winnega M; Leventhal BL; Cook EH
    J Am Acad Child Adolesc Psychiatry; 2005 Apr; 44(4):343-8. PubMed ID: 15782081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
    Kronenberg S; Apter A; Brent D; Schirman S; Melhem N; Pick N; Gothelf D; Carmel M; Frisch A; Weizman A
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):741-50. PubMed ID: 18315446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders.
    Scahill L; McCracken JT; Bearss K; Robinson F; Hollander E; King B; Bregman J; Sikich L; Dukes K; Sullivan L; Anagnostou E; Donnelly C; Kim YS; Ritz L; Hirtz D; Wagner A
    J Autism Dev Disord; 2012 Mar; 42(3):432-40. PubMed ID: 21667200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
    Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
    Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.
    Lenze EJ; Goate AM; Nowotny P; Dixon D; Shi P; Bies RR; Lotrich FK; Rollman BL; Shear MK; Thompson PA; Andreescu C; Pollock BG
    J Clin Psychopharmacol; 2010 Dec; 30(6):672-7. PubMed ID: 21105279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
    Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
    Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderation of antidepressant response by the serotonin transporter gene.
    Huezo-Diaz P; Uher R; Smith R; Rietschel M; Henigsberg N; Marusic A; Mors O; Maier W; Hauser J; Souery D; Placentino A; Zobel A; Larsen ER; Czerski PM; Gupta B; Hoda F; Perroud N; Farmer A; Craig I; Aitchison KJ; McGuffin P
    Br J Psychiatry; 2009 Jul; 195(1):30-8. PubMed ID: 19567893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
    Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
    Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.
    Zhong H; Haddjeri N; Sánchez C
    Psychopharmacology (Berl); 2012 Jan; 219(1):1-13. PubMed ID: 21901317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
    Won ES; Chang HS; Lee HY; Ham BJ; Lee MS
    Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study.
    Outhred T; Das P; Dobson-Stone C; Felmingham KL; Bryant RA; Nathan PJ; Malhi GS; Kemp AH
    Aust N Z J Psychiatry; 2014 Dec; 48(12):1115-25. PubMed ID: 24810870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLC6A4 variation and citalopram response.
    Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
    Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.
    Garfield LD; Dixon D; Nowotny P; Lotrich FE; Pollock BG; Kristjansson SD; Doré PM; Lenze EJ
    Am J Geriatr Psychiatry; 2014 Oct; 22(10):971-9. PubMed ID: 24021217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.